SEC Form 4	
------------	--

[ ]

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average bi	urden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

	ction 1(b).			F							ities Exchan		.934			Linours	perie	sponse:	0.5		
1. Name and Address of Reporting Person* Lloyd Brian G.						or Section 30(h) of the investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol <u>MERIT MEDICAL SYSTEMS INC</u> [ MMSI								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
(Last) (First) (Middle)					_ ]	]								Director 10% Owner Constraints of the second secon							
1600 WEST MERIT PARKWAY						3. Date of Earliest Transaction (Month/Day/Year) 05/07/2021									CHIEF LEGAL OFFICER, SECRETARY						
(Street) SOUTH UT 84095 JORDAN				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting								
(City) (State) (Zip)														Person							
		Tal	ble I - No	on-Der	ivativ	ve S	ecuri	ties A	cquired	l, Di	sposed o	of, or Be	nefici	ially C	Owned						
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)		e, Transaction Disposed Code (Instr.		es Acquired Of (D) (Insti		and 5) Securit Benefic		es ally =ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
									Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)						
	Stock, No				7/2021				M		5,000 5,000			).72 .62 <sup>(1)</sup>							
Common Stock, No Par Value Common Stock, No Par Value				3/202	-			G	v	2,343			i02(1)	5,696		$\vdash$	D				
			Table II				curiti	es Ac	quired,	 Dis	posed of,						<u> </u>				
				(e.g.,			lls, w	arran	ts, optio	ons,	converti	ble secu	irities	s)							
1. Title of Derivative Security (Instr. 3)	e Conversion Date Exec or Exercise (Month/Day/Year) if an			ied 1 Date, ay/Year)		Insaction of E		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4)		Derivative Security				10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Natu of Indire Benefici Ownersl (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisal	ble	Expiration Date	Title	Amou or Numb of Share	er							
Non- qualified stock options (right to buy)	\$19.72	05/07/2021			М			5,000	05/02/201	L7 <sup>(2)</sup>	05/02/2023	Common Stock	5,00	0	\$0	0		D			
Non- qualified stock options (right to buy)	\$28.2								04/14/201	18 <sup>(3)</sup>	04/14/2024	Common Stock	50,00	00		50,000		D			
Non- qualified stock options (right to buy)	\$44.8								03/02/201	19 <sup>(4)</sup>	03/02/2025	Common Stock	25,00	00		25,00	0	D			
Non- qualified stock options (right to buy)	\$55.73								03/01/202	20 <sup>(5)</sup>	03/01/2026	Common Stock	30,00	00		30,00	0	D			
Non- qualified stock options (right to buy)	\$37.71								02/26/202	21(6)	02/26/2027	Common Stock	16,72	22		16,72	2	D			
Non- qualified stock options (right to buy)	\$56.25								03/19/202	22 <sup>(7)</sup>	03/19/2028	Common Stock	9,68	1		9,681	L	D			

Explanation of Responses:

1. The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$64.51 to \$65.10, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

2. Become exercisable in equal annual installments of 20% commencing on 05/02/2017.

- 3. Become exercisable in equal annual installments of 20% commencing on 04/14/2018.
- 4. Become exercisable in equal annual installments of 20% commencing on 03/02/2019.
- 5. Become exercisable in equal annual installments of 20% commencing on 03/01/2020.
- 6. Become exercisable in equal annual installments of 25% commencing on 02/26/2021.7. Become exercisable in equal annual installments of 25% commencing on 03/19/2022.

## /s/ Brian G. Lloyd

\*\* Signature of Reporting Person

Date

05/10/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.